Zhu et al developed a model for predicting the total daily dose of warfarin based on the patient's physical and genotypic features. This can control for a number of factors affecting the variability in dose. The authors are from the University of Louisville, Luminex Molecular Diagnostics and PGXL Laboratories.
VKORC1 = vitamin K epoxide reductase complex, subunit 1
CYP = cytochrome P450
Parameters:
(1) age in years
(2) gender
(3) body weight in pounds
(4) VKORC1 (-1639AA) genotype
(4) VKORC1 (-1639BB) genotype
(6) CYP2C9*2 genotype
(7) CYP2C9*3 genotype
Parameter |
Finding |
Points |
---|---|---|
gender |
female |
0 |
|
male |
1 |
VKORC1 (-1639AA) |
AA |
1 |
|
GA |
0 |
|
GG |
0 |
VKORC1 (-1639GG) |
AA |
0 |
|
GA |
0 |
|
GG |
1 |
CYP2C9*2 |
0 alleles |
0 |
|
1 allele |
1 |
|
2 alleles |
2 |
CYP2C9*3 |
0 alleles |
0 |
|
1 allele |
1 |
|
2 alleles |
2 |
where:
• The alleles of CYP2C9 associated with decreased metabolic activity and increased risk of bleeding during warfarin therapy: CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6.
X =
= (-0.008 * (age in years)) + (0.116 * (points for gender)) + (0.004 * (weight in lbs)) - (0.376 * (points for VKORC1 1639AA)) + (0.271 * (points for VKORC1 1639GG)) - (0.307 * (points for CYP2C9*2)) - (0.318 * (points for CYP2C9*3)) + 1.35
daily dose in mg =
= EXP(X)
Purpose: To determine a patient's total oral daily dose of warfarin using the model of Zhu et al.
Specialty: Hematology Oncology, Clinical Laboratory, Pharmacology, clinical
Objective: dosage calculations
ICD-10: I74, I81, I82, O88, T79.0, T79.1,